Kymera Therapeutics, Inc. KYMR
Set alert
At close · Nov 2
After hours · Nov 2, 4:33 PM ET
- YTD
- +63.87%
- 1 year
- +106.19%
- Open
- 127.00
- Prev close
- 126.63
- Mkt cap
- 10.89B
- Vol
- 1.29M
- Avg vol
- 774.47K
- EPS
- -3.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 124.30
- High
- 129.34
- Forward P/E
- -25.30
- Beta
- 2.03
- Short ratio
- 10.32
- Inst. own
- 116.24%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 114.92
- 200-d avg
- 96.42
- 1y target
- 144.39
5D chart
Events in this range
- Oct 27, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 29, 2026Earnings: -1.32; estimate -1.26; surprise -4.76%
- Oct 29, 2026Rating: BTIG · Buy → Buy
- Oct 30, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 30, 2026Rating: Truist Securities · Buy → Buy
- Nov 2, 2026Rating: Barclays · Overweight → Overweight
Signals (117)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 9:50 AM | 8 hours ago |
| SMA: Bearish | Nov 2, 9:45 AM | 8 hours ago |
| MACD: Sell Signal | Nov 2, 9:45 AM | 8 hours ago |
| MACD: Buy Signal | Oct 30, 3:50 PM | 3 days ago |
| RSI: Overbought | Oct 30, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:10 PM | 3 days ago |
| RSI: Overbought | Oct 30, 2:40 PM | 3 days ago |
| RSI: Overbought | Oct 30, 2:30 PM | 3 days ago |
| RSI: Overbought | Oct 30, 2:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:55 PM | 3 days ago |
| RSI: Overbought | Oct 30, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 3 days ago |
| RSI: Overbought | Oct 30, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:50 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 4 days ago |
| RSI: Oversold | Oct 29, 10:50 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 5 days ago |
| RSI: Overbought | Oct 28, 1:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 5 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 27, 2:50 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 27, 11:45 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 6 days ago |
News
-
2 hours ago benzinga.com
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $139 to $170.
-
3 days ago benzinga.com
Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150
Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.
-
3 days ago benzinga.com
RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116
RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.
-
4 days ago benzinga.com
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.
4 days ago seekingalpha.com
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
4 days ago marketbeat.com
Kymera Therapeutics Q3 Earnings Call Highlights
Kymera Therapeutics NASDAQ: KYMR reported third-quarter results and outlined progress across its clinical pipeline, including phase I healthy-volunteer data for KT-579, an oral degrader targeting…
-
4 days ago benzinga.com
Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.27) by 3.94 percent. This is a 40.43 percent decrease over losses…
4 days ago globenewswire.com
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile
5 days ago globenewswire.com
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader…
-
6 days ago benzinga.com
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146
Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.
1 week ago globenewswire.com
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader…
2 weeks ago zacks.com
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
3 weeks ago prnewswire.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation…
3 weeks ago benzinga.com
This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiate coverage: Outperform on American Express and Kymera, Overweight on Kratos, Hold on IBM and Neutral on Duos.
-
3 weeks ago benzinga.com
Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140
Raymond James analyst Thomas Deal initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $140.
-
4 weeks ago benzinga.com
Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150
Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $150.
1 month ago prnewswire.com
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR)…
-
1 month ago benzinga.com
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152
Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.
1 month ago seekingalpha.com
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.
1 month ago seekingalpha.com
Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
1 month ago zacks.com
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
1 month ago defenseworld.net
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR
Atlas Venture Life Science Advisors LLC lessened its stake in Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 37.8% in the second quarter, according to the company in its most recent disclosure with the…
2 months ago zacks.com
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
2 months ago globenewswire.com
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader…
2 months ago globenewswire.com
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial…
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.
2 months ago defenseworld.net
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp
Bank of New York Mellon Corp purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) in the undefined quarter, according to its most recent filing with the Securities and…
-
2 months ago benzinga.com
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151
Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.
2 months ago zacks.com
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
-
2 months ago benzinga.com
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.
2 months ago seekingalpha.com
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Kymera Therapeutics Q2 Earnings Call Highlights
Kymera Therapeutics NASDAQ: KYMR said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by…
2 months ago zacks.com
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.95 per share a year ago.
-
2 months ago benzinga.com
Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of…
3 months ago benzinga.com
This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
-
3 months ago benzinga.com
Deutsche Bank Initiates Coverage On Kymera Therapeutics with Hold Rating, Announces Price Target of $120
Deutsche Bank analyst David Hoang initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Hold rating and announces Price Target of $120.
-
3 months ago benzinga.com
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $135
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $125 to $135.
-
3 months ago benzinga.com
Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $140
Mizuho analyst Joseph Catanzaro maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $120 to $140.
-
3 months ago benzinga.com
RBC Capital Downgrades Kymera Therapeutics to Sector Perform, Raises Price Target to $115
RBC Capital analyst Brian Abrahams downgrades Kymera Therapeutics (NASDAQ:KYMR) from Outperform to Sector Perform and raises the price target from $106 to $115.
-
4 months ago benzinga.com
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $110 to $125.
-
4 months ago benzinga.com
Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $136
Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $116 to $136.
-
4 months ago benzinga.com
B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $117 to $155.
-
4 months ago benzinga.com
Canaccord Genuity Maintains Buy on Kymera Therapeutics, Raises Price Target to $129
Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $106 to $129.
4 months ago benzinga.com
Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
Kymera Therapeutics shares surged after completing KT-621 Phase 2b enrollment early, accelerating data timing and Phase 3 plans.
-
4 months ago benzinga.com
BTIG Reiterates Buy on Kymera Therapeutics, Maintains $134 Price Target
BTIG analyst Jeet Mukherjee reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $134 price target.
4 months ago benzinga.com
Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High
U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, while consumer discretionary fell 1.1%. Core PCE rose 3.4% in May.
4 months ago benzinga.com
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.
-
4 months ago benzinga.com
Kymera Therapeutics Completes Enrollment In Global BROADEN2 Phase 2b Trial Of KT-621, Oral STAT6 Degrader, For Treatment Of Moderate To Severe Atopic Dermatitis
BROADEN2 enrollment completed nearly six months ahead of anticipated timelinesKT-621 Phase 3 trials in AD planned to initiate by mid-2027KT-621 BREADTH Phase 2b asthma trial ongoing, with data…
-
4 months ago benzinga.com
Kymera Therapeutics Appoints Felix J. Baker Board Chairman, Succeeding Bruce Booth
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the…